Major Depressive disorder. Depressive episode
Conditions
Interventions
Intervention 1: Tablet serteraline 200 mg/day plus capsule memantine 20mg/day as intervention group for 6 weeks. Intervention 2: Tablet serteraline 200mg/day plus Cap. placebo as control group for 6 w
Treatment - Drugs
Placebo
Tablet serteraline 200 mg/day plus capsule memantine 20mg/day as intervention group for 6 weeks
Tablet serteraline 200mg/day plus Cap. placebo as control group for 6 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: presence of Major Depressive Disorder based on DSM-IV criteria; baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22; signing informed consent. Exclusion criteria: presence of psychosis; any diagnosis in Axis I and II; receiving psychotropic medications; receiving any antidepressants during past one month or ECT during past two months; presence of hypo or hyperthyroidism or cardiovascular problems; pregnancy and breast feeding.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of depression. Timepoint: Baseline and weeks 2-4-6 after beginig of treatment. Method of measurement: By Hamiltion Depression Rating Scale 17-Item. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed